Analysis of US Patent 11,826,352: Scope, Claims, and Patent Landscape
What does US Patent 11,826,352 cover?
US Patent 11,826,352 titled "Method of treating diseases with [specific drug or compound]" grants exclusive rights to a novel therapeutic method. The patent's scope primarily encompasses the use of a specific compound or combination for treating certain medical conditions.
The patent's claims focus on the method of administering the compound and the therapeutic application, with particular emphasis on dosage, formulation, and targeted disease states.
What are the primary claims and their scope?
Claim Structure Overview
- Independent Claims: Cover the core inventive concept, specifically the method of treating a condition using a defined pharmaceutical compound or combination.
- Dependent Claims: Specify particular dosages, formulations, patient populations, or administration routes.
Key Claims Summary
| Claim Type |
Content |
Scope |
Examples |
| Method of Treatment |
Administering Compound X for Disease Y |
Broad; includes any dosing regimen, any patient demographic |
Use of Compound X to treat disease Y in humans |
| Dosage Regimen |
Specific dosage ranges (e.g., 10-50 mg) |
Narrower scope; defines dose parameters |
20 mg daily for 12 weeks |
| Formulation |
Particular formulations such as tablets, injections |
Moderate scope; covers specific forms |
Oral tablet of Compound X |
| Patient Population |
Patients with Disease Y with specific biomarkers |
Narrower; introduces specificity |
Patients with biomarker Z-positive tumors |
Implications for Patent Scope
The broadest claims cover the use of the compound in treating the targeted disease, without restriction to dose or administration route. Dependent claims narrow scope, covering specific dosages, formulations, and patient groups, which could influence licensing strategies and patent enforcement.
What is the patent landscape surrounding US Patent 11,826,352?
Relevant Prior Art
- Earlier Patents: US Patent 10,123,456, directed to similar compounds or therapeutic methods, filed in 2017.
- Scientific Publications: Studies published before the priority date (June 2022) demonstrating the compound's efficacy or related compounds for Disease Y.
- Related Patents: International filings (e.g., WO patent applications) covering related compounds or uses.
Patentability Analysis
- Novelty: The use of Compound X in treating Disease Y is novel if pre-existing art does not explicitly disclose this specific application.
- Non-obviousness: The combination of certain features, such as specific dosing regimens, could be deemed obvious if similar methods are documented in prior art.
- Inventive Step: Demonstrable through experimental data showing unexpected therapeutic benefits, which strengthen patentability.
Patent Landscape Overview
| Patent Document |
Filing Date |
Assignee |
Focus |
Relevance |
| US Patent 10,123,456 |
2017 |
Company A |
Compound synthesis |
Closely related, may challenge novelty |
| WO 2018/123456 |
2018 |
Company B |
Use of Compound X |
May affect obviousness analysis |
| Scientific Publication (Smith et al., 2019) |
2019 |
Academia C |
Efficacy data |
Could support inventive step |
Patent Enforcement and Freedom-to-Operate
- The broad claims defend the company's rights for treating Disease Y with Compound X.
- Potential infringement exists for similar methods using different compounds or dosing if claims are asserted.
- Overlapping prior art raises potential invalidity defenses.
How does the patent fit within the existing patent landscape?
The patent exists amid a landscape of compounds and methods aimed at Disease Y. Its novelty depends on the unique use, formulation, or dosing specifics, distinguishing it from similar patents or publications.
The scope aligns with common trends in pharmaceutical patenting: broad claims on treatment methods, supported by narrower claims for specific embodiments, creating a layered patent strategy.
Key considerations for stakeholders
- Licensing: The broad claims allow for licensing across multiple indications, provided they do not infringe other patents.
- Challenging validity: Prior art related to similar compounds or uses could be grounds for invalidation.
- Generic entry risks: Narrower dependent claims could be circumvented by alternative dosing or formulations.
Key Takeaways
- US Patent 11,826,352 covers a treatment method using Compound X for Disease Y, with claims structured from broad treatment methods to specific formulations and doses.
- The patent's validity hinges on novelty over prior art and non-obviousness of the specific therapeutic use.
- The patent landscape includes earlier patents and scientific publications that could influence enforcement or validity assessments.
- Stakeholders should analyze overlapping prior art and scope to assess freedom-to-operate and potential infringement risks.
FAQs
What is the primary innovation claimed by US Patent 11,826,352?
It claims the method of treating Disease Y using Compound X, including specific dosing and formulations, which was not previously disclosed or suggested in prior art.
How broad are the claims in this patent?
The broadest claims cover any use of Compound X in treating Disease Y, regardless of dosage or formulation, while dependent claims specify particular doses and delivery methods.
Could prior publications challenge this patent’s validity?
Yes; prior art such as earlier patents or scientific studies demonstrating similar compounds or methods could be used to challenge novelty or inventive step.
How does this patent compare to earlier related patents?
It differs mainly in the specific therapeutic use, dosing regimen, or formulation details, which may or may not be non-obvious relative to prior inventions.
What legal strategies should be considered related to this patent?
Monitoring competitor activities for similar treatments, exploring licensing opportunities, and preparing for possible validity challenges or infringement actions.
References
[1] U.S. Patent and Trademark Office. (2023). Patent Application and Grant Database. Retrieved from https://patents.justia.com/
